Welcome to the Cancer IO Sebinar Session III: ‘Single-cell tumor immunity’ on 16th of September 2021, 15:00-16:45 EEST!
This is the third session of the bi-monthly Cancer IO sebinar (webinar + seminar) series. Welcome to join the event in Zoom. The event is open to all interested in this fascinating topic. More information below and in LinkedIn.
Students can receive credits for this seminar, where 1 ETSF is given to students who attend 5 sebinars and hand in a ½ page layman’s abstracts for each of these. Instructions will be provided at the start of each sebinar. Registration is open on WebOodi.
This interactive bi-monthly sebinar series aims to bring you the newest developments in the field of immuno-oncology presented by leading scientists. Every sebinar will have an important interactive element in the form of a panel discussion, where the invited speaker discusses a timely topic with local scientists and clinicians. Sebinar attendants are welcomed to participate in the discussion using the Q&A feature.
This time we will hear about the latest developments in single-cell sequencing and spatial transcriptomics in regards of tumor immunity. In the panel discussion, we address if and how these new technologies can be taken from basic research tools towards clinical diagnostics. Our invited speaker Bernd Bodenmiller holds a dual professorship with the University of Zurich (Institute of Molecular Life Sciences and Department of Quantitative Biomedicine).
15:00 - 15:10 Introduction: Single-cell resolution to immune responses
MD PhD, Group Leader Anniina Färkkilä (University of Helsinki, Finland)
15:10 - 15:20 Spatial solutions for single-cell omics
CEO Päivi Saavalainen (SCellex)
15:20 - 16:10 Profiling tumor immunity at single-cell level
Prof. Bernd Bodenmiller (University of Zurich)
16:10 - 16:20 Q&A
16:20 – 16:45 Panel Discussion: Single-cell pathology – Utopia or reality?
Panelists: Bernd Bodenmiller, Anniina Färkkilä, Päivi Saavalainen, Eevi Kaasinen (University of Helsinki)
Session Chair: Heidi Haikala, Cancer IO
Biography for Dr. Bernd Bodenmiller:
Professor Bernd Bodenmiller was appointed Associate Professor of Quantitative Biomedicine in the Department of Biology. He holds a dual professorship with the University of Zurich. Bernd Bodenmiller’s research investigates the mechanisms of cancer ecosystems. His work identified novel tumor and immune cell phenotypes associated with clinical features, signaling mechanisms leading to therapy resistance, and experimental and computational methods to image tissues in a highly multiplexed manner in situ. These methods are widely used by researchers and also in clinical studies. Bernd Bodenmiller has developed an excellent international network and has received several awards, including an ERC Starting Grant and an ERC Consolidator Grant. In addition, he is the founding director of the Department of Quantitative Biomedicine at the University of Zurich.
After his graduate studies in biochemistry at ETH Zurich and a PhD in the lab of Ruedi Aebersold (2004 to 2008), he continued his research with two postdoctoral positions in the Aebersold lab and the Nolan lab (Stanford). In 2013, he returned to Zurich where he obtained an SNSF assistant professorship at the Institute of Molecular Life Sciences (University of Zurich). Since 2019, Bernd Bodenmiller is the director of the Department of Quantitative Biomedicine (UZH).
Jackson HW, Fischer JR, Zanotelli VRT, Ali HR, Mechera R, Soysal SD, Moch H, Muenst S, Varga Z, Weber WP, Bodenmiller B: The single-cell pathology landscape of breast cancer. Nature 2020 Feb; 578(7796):615-620.
Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, Rees M, Ramaswamy A, Muenst S, Soysal SD, Jacobs A, Windhager J, Silina K, van den Broek M, Dedes KJ, Rodríguez Martínez M, Weber WP, Bodenmiller B: A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 2019 May 16;177(5):1330-1345.e18.
Damond N, Engler S, Zanotelli VRT, Schapiro D, Wasserfall CH, Kusmartseva I, Nick HS, Thorel F, Herrera PL, Atkinson MA, Bodenmiller B: A map of human type I diabetes progression by imaging mass cytometry. Cell Metabolism 29(3): 755-768.E5
Chevrier S, Crowell HL, Zanotelli VRT, Engler S, Robinson MD, Bodenmiller B: Compensation of signal spillover in suspension and imaging mass cytometry. Cell Systems 6(5), 612-620 (2018).
Schulz D, Zanotelli VRT, Fischer JR, Schapiro D, Engler S, Lun XK, Jackson, HW, Bodenmiller B: Simultaneous multiplexed imaging of mRNA and proteins with subcellular resolution in breast cancer tissue samples by mass cytometry. Cell Systems 6(1), 25 - 36 (2018).
Schapiro D, Jackson HW, Raghuraman S, Fischer JR, Zanotelli VRT, Schulz D, Giesen C, Catena R, Varga Z, Bodenmiller B: HistoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. Nature Methods 14, 873–876 (2017).
Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe’er D, Bodenmiller B: An immune atlas of clear cell renal cell carcinom. Cell 169(4), 736 - 749 (2017).
Lun XK, Zanotelli VRT, Wade JW, Schapiro D, Tognetti M, Dobberstein N, Bodenmiller B: Influence of node abundance on signaling network state and dynamics analyzed by mass cytometry. Nature Biotechnology 35, 164–172 (2017).
Giesen C, Wang HAO, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, Schueffler PJ, Grolimund D, Buhmann JM, Brandt S, Varva Z, Wild PJ, Guenther D, Bodenmiller B: Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nature Methods 11, 417–422 (2014).